Vitro Biopharma, Inc. was founded with the core mission of translating scientific advancements into transformative medicines for patients suffering from autoimmune diseases and inflammatory disorders. The company specializes in developing Wharton's jelly-derived cell therapies, aiming to become a leader in creating differentiated product candidates swiftly and efficiently. Vitro Biopharma primarily serves the immunology and inflammatory disease markets within the United States.

Notable affiliated individuals include key scientists and industry experts who drive the company's innovative research and development efforts. Vitro Biopharma has garnered attention from prominent investors in the biotech sector, contributing to its growth and credibility. The company has achieved significant milestones in preclinical and clinical trials, underscoring its potential impact on treating complex diseases. By focusing on cutting-edge cellular therapies, Vitro Biopharma is poised to make substantial contributions to the field of biotechnology and patient care.